Objective. To estimate the incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK.
Introduction
Previous estimates of incidence and prevalence of granulomatosis with polyangiitis (GPA, formerly known as Wegener's granulomatosis) vary widely and have mainly been from small studies with low numbers of cases [1] . In addition, there are few data on influence of ethnic group, gender and age on incidence.
To improve the evidence base, a large study is needed that captures the full spectrum of people with this illness. Studies of disease incidence based on hospital case series in specialist centres may miss the mildest and most severe cases, as they may never be referred to the specialist centre, or may die before referral can be arranged. Studies based in primary care have the potential to reduce such referral bias, but may miss the most severe cases that are diagnosed in hospital and die before accessing primary care services again. Ideally, a cohort is needed with case ascertainment in both primary and secondary care.
The aim of this study is to estimate the incidence, prevalence and mortality of GPA in a UK populationbased cohort, using both general practitioner (GP) and hospital records contained within the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) datasets, during 19972013.
Patients and methods

Study design and study population
This is a historical cohort study containing the 398 practices in the CPRD with data linked to HES (65% of patients in the whole CPRD). The CPRD is a longitudinal database of anonymized medical records from GPs. Patients are broadly representative of the UK population in terms of age, sex and ethnicity [2] . The HES contains records of all inpatient stays and day case attendances in England. Primary and secondary diagnoses from each admission are coded using the 10th revision of the World Health Organization International Statistical Classification of Diseases and Related Health Problems (ICD-10).
We included people contributing data to CPRD-HES between 1 April 1997 and 31 December 2013. Patients were eligible for periods of time where their CPRD records were deemed to be of acceptable standard for research by the CPRD [2] .
Case definition
Cases had a diagnosis of GPA by either Read code in the CPRD or ICD-10 code in HES. To select relevant diagnosis codes, the Read code and ICD-10 dictionaries were searched using the terms GPA and the condition's former name, Wegener's granulomatosis. This identified only one relevant and specific code in each: Read code G754 and ICD-10 code M31.3, both for Wegener's granulomatosis. The Read code has previously been validated [3] , and work had previously been undertaken locally to validate the ICD-10 code, as described in the Discussion. The diagnosis date was taken as first occurrence of a code for vasculitis or GPA in a patient with a CPRD or ICD-10 code for GPA, as we considered it unlikely that two types of vasculitis would co-exist in the same person. Incident cases had a first record of a code for GPA during the study period, and included only patients with at least 1 year of follow-up from practice registration prior to diagnosis to try to minimize the number of prevalent cases misclassified as incident [4] . The denominator was all the people who contributed research standard data to the CPRD-HES during the study dates [2] .
Statistical analysis
We categorized age into groups (015, 1639, 4054, 5569, 7084, 85+ years). Self-reported ethnicity was coded according to the Office for National Statistics 5 + 1 categories (White, Mixed, Asian, Black, Chinese or other and unknown). In addition, to improve statistical power, we recoded ethnicity as White vs Black and Minority Ethnic (BME) vs unknown. We also performed a sensitivity analysis by re-categorizing those with unknown ethnicity as White.
We calculated crude annual incidence rates/million person-years, and stratified these by age group, sex and ethnic group. Unadjusted incidence rate ratios (IRRs) were obtained by fitting variables individually in separate Poisson regression models. Mutually adjusted IRRs were obtained by fitting age, sex and ethnic group as a priori confounders in a single Poisson model. We calculated point prevalence/million people on 1 July 2013 and stratified this in the same way as for incidence. We used logistic regression to calculate odds ratios.
We used KaplanMeier methods to estimate survival in patients with GPA at pre-specified times following diagnosis (30, 90 days and 1 year) and stratified mortality rates by source of case identification (CPRD with or without a HES diagnosis vs identified by HES only), age, sex and ethnicity. We used Cox proportional hazards models to compare hazard ratios.
We used direct standardization of CPRD/HES age and sex-specific incidence rates to the age and sex-stratified UK population in 2016 [5] , to estimate the number of expected incident cases in the UK, and applied our mortality estimate to predict how many would die within 12 months. We estimated prevalence from the total population of the UK in 2016. All analyses were performed using Stata 14 statistical software (Statacorp, TX, USA).
For purposes of comparison with the previous CPRD study [3] , we re-ran our analyses using CPRD-only data (the whole of the CPRD, including those people from practices without linked HES data), which we report in a sensitivity analysis. 
Results
Overall, we identified 462 incident cases of GPA in CPRD-HES (see Fig. 1 ). The cohort had a slight male predominance (56.7% male) and mean (S.D.) age at diagnosis of 60.0 (15.9) years.
Incidence
We estimated the overall incidence rate to be 11.8 (95% CI: 10.7, 12.9)/million person-years based on 462 cases of GPA in 39 286 088 person-years of follow-up. The incidence in children (aged <16 years) was 0.88 (95% CI: 0.40, 1.96)/million person-years, and among adults (516 years) was 14.0 (95% CI: 12.8, 15.4)/million person-years.
Temporal trend
The incidence by year is shown in Table 1 . The annual incidence in CPRD-HES appears to have increased during the first few years of the study period, but there was no significant change from 2000 onwards (IRR/year 1.02, 95% CI: 0.99, 1.04, P-trend = 0.2).
Age and gender
Crude incidence rates and adjusted rate ratios are presented in Table 2 . Incidence was lower among women than among men, with adjusted IRR 0.67 (95% CI: 0.56, 0.81, P < 0.001). Peak age of incidence was at 5569 years (IRR = 6.8, 95% CI: 4.9, 9.6, P < 0.001, compared with 1639 years) and similar at 7084 years (IRR = 6.4, 95% CI: 4.5, 9.1, P < 0.001, compared with 1639 years).
Ethnicity
We identified ethnicity for 90.7% of cases of GPA, but only 76.8% of the denominator CPRD-HESlinked population (see supplementary Table S1 , available at Rheumatology Online). The unknown denominator population was half as large as the White population, and three times the size of the BME population. Crude incidence was highest in the White ethnic group (16.2, 95% CI: 14.7, 17.9)/million person-years, intermediate in the BME group (7.9, 95% CI: 5.5, 11.3) and lowest in the group with unknown ethnicity (3.7, 95% CI: 2.8, 5.0). In analysis adjusted for age and sex, the results were similar but slightly attenuated: the IRR for BME compared with Whites was 0.64 (95% CI: 0.44, 0.94) and for people of unknown ethnicity compared with Whites was 0.30 (95% CI: 0.22, 0.41).
In the sensitivity analysis, people of unknown ethnicity were re-categorized as White. There was a lower incidence in the BME compared with White populations in crude incidence (IRR = 0.64, 95% CI: 0.44, 0.94, P = 0.01), but this was partly explained by the younger age-structure of the BME population, and once adjusted for age and sex the effect was reduced and non-significant at the 5% level (IRR = 0.81, 95% CI: 0.56, 1.18, P = 0.3) ( Table 2) .
Prevalence
In 2013, the overall prevalence was 134.9 (95% CI: 121.3, 149.6). The prevalence among adults was 163.8 (95% CI: 147.2, 181.7)/million and among children (age <16 years) was 4.2 (95% CI: 0.5, 15.0) ( Table 3 ). In analysis mutually adjusted for age, sex and ethnicity, prevalence was lower among women than among men (OR = 0.79, 95% CI: 0.64, 0.97, P = 0.027), highest in the 7084 age group (OR = 8.5, 95% CI: 5.7, 12.5 compared with the 1639 age group, P < 0.0001), and lower in the BME than White population (OR = 0.57, 95% CI: 0.39, 0.84, P = 0.002).
Mortality
One hundred and twenty of 462 patients died in 2049 person-years of follow-up, giving a mortality rate of 58.6/1000 person-years (Table 4) . Mortality was 4.8% (95% CI: 3.2, 7.2%) at 30 days, 9.9% (95% CI: 7.5,
FIG. 1 Flow diagram of ascertainment of incident cases of granulomatosis with polyangiitis
Cases ascertained from the CPRD-HES. Acceptable patient records and periods where practices record up to standard data are quality standards for research devised by the CPRD.
a In order to exclude prevalent cases. CPRD:
Clinical Practice Research Datalink; HES: Hospital Episode Statistics. From mutually adjusted analysis using the likelihood ratio test. BME: Black/Minority Ethnic.
identified only in HES only compared with cases identified in CPRD with or without a HES diagnosis (HR = 2.3, 95% CI: 1.6, 3.4, P < 0.0001). This is shown in the KaplanMeier survival estimates for people with GPA presented separately by source of case ascertainment, which are shown in Fig. 2 .
Estimated UK incidence
We estimate that at present each year in the UK there will be 700 new cases of GPA, of whom 95 will die within 12 months. We estimate that there are 8750 people living with GPA in the UK in 2016.
Sensitivity analysis (use of data from all CPRD practices)
We identified 574 incident cases of GPA during 19952014 in the whole CPRD (see supplementary Fig. S1 , available at Rheumatology online). Similar to CPRD-HES, there was a slight male predominance (54.9% male) and a similar age at diagnosis [mean 58.6 (S.D. 15.8) years]. The estimated incidence was lower at 8.1 (95% CI: 7.5, 8.8)/million person-years. The effect of age and gender were similar (see supplementary Tables S2 and S3 , available at Rheumatology Online). The incidence was stable throughout the period. The mortality rate was also lower: 125 patients of 574 died in 3002.2 person-years of follow-up, giving a mortality rate of 41.6/1000 person-years, with mortality 2.1% at 30 days, 4.0% at 90 days and 8.5% at 1 year.
Discussion
Main findings
Our estimate of the incidence of GPA in the UK is 11.8/million person-years, which is higher than previous estimates. The incidence has been stable from 2000 onwards, is higher in men than in women and is highest in older age groups. The incidence was lower in the BME than White population in crude analyses, but this was partially explained by the different age and sex distribution of the BME population. The prevalence of GPA was 134.9/ million in 2013, higher in men than women, and highest in the 7085 age group. Prevalence was lower in BME than in White people, and this was again partially explained by confounding by age and sex. Mortality among people with GPA was 14% at 1 year, and was significantly worse among those identified in hospital than among those identified in GP records.
Strengths
To our knowledge this is the first study that has combined general-populationbased and hospital case ascertainment. Our comparator analysis with case ascertainment from primary care records (CPRD-only) shows that case ascertainment using both primary and secondary care is a more sensitive method, and that it allows identification of an important group of patients with the highest mortality. Compared with case ascertainment in secondary care only, this method is also more sensitive, and identifies a group of patients with lower mortality.
To our knowledge, this is one of the largest studies of GPA ever conducted. The largest previous studies both report cases identified prior to 2000 and identified cases using hospital discharge registers in Sweden (n = 1938) and Finland (n = 492) [68] , which are difficult to compare with our study as they both report a rising incidence during their study periods, which is at least partially explained by increased recognition of the condition due to the introduction of routinely available ANCA-testing during the 1990s. The largest recent study was the previous CPRD study, which identified 295 incident cases [3] . Our analysis of 462 cases has given the analyses greater power, allowing estimates such as incidence and prevalence in the paediatric (<16 years) population. This study is also the first in the CPRD, and second in the UK, to include ethnicity, and provide predictions for planning health services for the BME population.
Limitations
The main limitation of this study is lack of power, which limits all studies of rare diseases. However, we have used the largest existing database of linked primary and secondary care records worldwide. Second, this study has limitations inherent in research using large databases of routinely collected healthcare information. In particular, the validity and date of each diagnosis could not be verified externally. However, the previous CPRD study examined the anonymized letters from 31 patients coded as G754, and the diagnosis of GPA was confirmed in 28 of those, giving a positive predictive value of 90% [3] . An additional 1 (4%) case had a diagnosis of microscopic polyangiitis, and in 2 (7%) the diagnosis could not be confirmed but it was likely they had some form of vasculitis. Our previous study, using multiple sources of case ascertainment to identify incident cases of ANCA-associated vasculitis [9] , found searching inpatient discharges using ICD-10 code M313 identified 119 cases in our local hospital between 2007 and 2013. Of these, review of the medical notes confirmed a diagnosis of GPA in 102, giving a positive predictive value of 86%. A further 10 cases (8%) had a diagnosis of microscopic polyangiitis, and only 7 (6%) had no evidence of systemic vasculitis. In both instances, the number of missed cases could not be estimated; however, we would expect that some patients were only ever coded as vasculitis and were missed by our search. It is most likely that our results are an underestimate of the true incidence and prevalence.
It is also possible that some prevalent cases may have been wrongly identified as incident, which would falsely increase our estimate of incidence. However, GP records should record previous significant diagnoses even in new registrations, and most relapses are in the first year after diagnosis, meaning that we will have excluded most prevalent cases from our incidence estimate by requiring 1 year of active follow-up prior to diagnosis. This method is the same as used previously [3] , and has been validated in a range of other chronic conditions in the CPRD [4] .
Fits in with other literature Overall, our estimate of incidence was higher than that of previous studies, and we think this was due to the more sensitive strategy of case ascertainment. In the last 10 years in Europe, estimates (which have been in studies of adults only) have ranged from 4.9/million adult-years in a hospital-based study in Southern Spain to 11.3/million adult-years in a hospital-based study in the UK (Norfolk) [6, 1014] , although it is unclear whether differences in methods of case ascertainment or true geographic differences account for the variation. Our incidence in the CPRD-only population of 8.1 (95% CI: 7.5, 8.8)/million person-years was very similar to that of the previous CPRD study conducted 19902005, in which the incidence was estimated to be 8.3 (95% CI: 7.5, 9.4) [3] , and this shows how incidence can be underestimated unless cases are ascertained from secondary as well as primary care. Our findings show a lower incidence in women compared with in men (which is in keeping with many [3, 1013, 15] , but not all [6, 16, 17] , previous smaller studies) and confirm the age group with the highest incidence to be 6070 years [3, 13] .
The incidence rose rapidly in both CPRD and HES databases in the first 5 years after inception of each database (1987 in the CPRD and 1997 in HES)-which is a finding common to database studies in other conditions and may reflect data collection practices [18] . After these times, each database showed a stable incidence. We did not find evidence of a cyclical pattern of incidence, which has been seen in other studies [10] .
A recent study has shown that CPRD-HES contain the same ethnic mix as the UK in the 2011 census, and that they provide reliable records of self-reported ethnicity [19] . Reliability is much higher for White vs BME differentiation than between BME ethnic groups, so we treated ethnicity as a binary variable (White vs BME) for most analyses. Frequency of ethnicity recording also increased after 1 April 2006, when recording ethnicity was introduced to the UK National Health Service Quality and Outcomes Framework; however, this only accounts for 22 of our 462 incident cases. We therefore have incomplete ethnicity data: available for 90.7% of cases, and only 76.8% of the denominator population. We used a worst-case scenario approach and re-coded the unknown group to White. This approach also reflects the 2011 census results, resulting in 86.2% of the denominator population being White compared with 85.2% in the 2011 census. We found that the incidence was lower in BME compared with in Whites-but this was not statistically significant at the 5% level. This is similar to our findings in a local hospital cohort of people with all types of ANCA-associated vasculitis (and complete ethnicity data), where the IRR adjusted for age and sex for BME compared with White people was 0.7, 95% CI: 0.3, 1.5, P = 0.3) [19] . However, we found the prevalence of GPA was lower in BME than in White populations, even after adjustment for age and sex (adjusted OR = 0.6, P = 0.004). It is possible that a survival bias explains our findings if the disease is more severe in the BME population, or that we only captured the more severe end of the spectrum for this group; however, we were unable to analyse the mortality rate difference between the White and BME groups, due to small numbers as there were only two deaths (among 29 patients) in the BME group. If the UK population ages as predicted in the coming years, and the age structure of the BME and White populations become more similar, we would expect to see an increase in the number of incident cases of GPA, and an increasing proportion from BME ethnic groups.
Our estimate of mortality at 1 year using CPRD-HES was higher than our estimate of mortality for the CPRD only, and as high as reported estimates from hospital studies. Increased mortality in cases ascertained from HES compared with CPRD has been found in other conditions [20] , which shows the importance of ascertaining cases from secondary care data in addition to GP records, as patients ascertained in hospital are more likely to be sicker. The lowest reported 1-year mortality of 17% comes from registry studies, or highly selective (tertiaryreferral) centres [21, 22] , where patients also have the lowest average age. An intermediate level of 511% is found in community studies [12, 23] . And the highest mortality of 1421% is reported from hospitals [7, 9, 24, 25] and clinical trials of patients with severe disease [26] . The highest mortality is in the first year after diagnosis; we did not find a bimodal increase in mortality after 8 years as reported by Luqmani and colleagues [23] . A recent systematic review of mortality confirms that ANCA-associated vasculitis has the highest mortality of the autoimmune rheumatic conditions [27] .
Conclusion
Our findings suggest that the incidence of GPA is stable over time, higher in men than in women, and highest in older people. We estimate that there will be 700 incident cases in the UK during 2016. Despite improvements in medical care, mortality is high, and higher than in other autoimmune rheumatic conditions. We predict that 95 people in the UK will die this year within 12 months of their GPA diagnosis. Estimates that do not include hospital data will underestimate both incidence and mortality. 
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